Medigene announces participation at six international conferences

Planegg - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming scientific and investor conferences:

CHI's Personalized Immunotherapy Meeting
Date: 2 - 3 May 2017
Location: Philadelphia, USA
Dr. Markus Dangl, Senior Vice President, Research & Pre-Clinical Development
gives an oral presentation on May 2nd at 11.30 AM on the topic: "High-Throughput Generation of Neoantigen-Specific T Cell Receptors for Adoptive T Cell Therapy"

Phacilitate's Investment for Advanced Therapies
Date: 3 May 2017
Location: London, UK
Medigenes CFO, Dr. Thomas Taapken, will participate in a panel discussion during this conference on the topic: "The opportunities of cell & gene therapy and why now?"

PEGS, CHI Fourth Annual Adoptive T Cell Therapy
Date: 3 - 4 May 2017
Location: Boston, USA
Dr. Markus Dangl, Senior Vice President, Research & Pre-Clinical Development, gives an oral presentation on May 3rd at 09.40 AM on the topic: "How Can We Utilize Neoantigens in Personalized Therapies for Patients with Tumors Having Low Mutation Profiles?"

BioEquity Europe
Date: 22 - 23 May 2017
Location: Paris, France
Medigenes CFO, Dr. Thomas Taapken, will hold a company presentation on May 22nd at 03.00 PM.

World Adoptive T-Cell Therapy Summit
Date: 29 - 30 May 2017
Location: Lisbon, Portugal

Phacilitate SIG: Automation
Date: 30 -31 May 2017
Location: Edinburgh, UK

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.